+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Thrombosis modulates arterial drug distribution for drug-eluting stents

Thrombosis modulates arterial drug distribution for drug-eluting stents

Circulation 111(13): 1619-1626

Drug-eluting stents deliver potent compounds directly to arterial segments but can become clot laden when deployed. The question arises as to whether thrombi affect drug elution and arterial uptake. Paclitaxel transport and retention were assessed in clots of different blood components. Diffusivity, affected by clot organization, is fastest in fibrin (approximately 347 microm2/s), slower in fibrin-red blood cell clots (34.98 microm2/s), and slowest in whole-blood clots (3.55 microm2/s). Blood cells bind and retain paclitaxel such that levels in clot increase linearly with red cell fraction. At physiological hematocrit, clot retains 3 times the amount of paclitaxel in surrounding solutions. Computational models predict that the potential of thrombus to absorb, retain, and release drug or to act as a barrier to drug delivery depends on clot geometry and strut position in clot relative to the vessel wall. Clot between artery and stent can reduce uptake 10-fold, whereas clot overlying the stent can shield drug from washout, increasing uptake. Model assumptions were confirmed and predictions were validated in a novel rat model that introduces thrombosis within stented aortas where nonocclusive thrombus acts as capacitive space for drug and shifts drug levels to decrease tissue uptake 2-fold. Thrombus apposed on stents creates large variations in drug uptake and can act to either increase or decrease wall deposition according to the clot and stent geometry. Arterial deposition of drug from stents deployed in clots will be highly variable and unpredictable unless the clot can be adequately controlled or removed.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 012693421

Download citation: RISBibTeXText

PMID: 15795325

DOI: 10.1161/01.cir.0000160363.30639.37

Related references

Modelling intravascular delivery from drug-eluting stents with biodurable coating: investigation of anisotropic vascular drug diffusivity and arterial drug distribution. Computer Methods in Biomechanics and Biomedical Engineering 17(3): 187-198, 2014

Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients. Jacc. Cardiovascular Interventions 6(12): 1267-1274, 2013

Frequency of coronary arterial late angiographic stent thrombosis (LAST) in the first six months: outcomes with drug-eluting stents versus bare metal stents. American Journal of Cardiology 99(6): 774-778, 2007

Very late thrombosis of a drug-eluting stent after discontinuation of dual antiplatelet therapy in a patient treated with both drug-eluting and bare-metal stents. Korean Circulation Journal 39(5): 205-208, 2009

Are drug-eluting stents associated with a higher rate of late thrombosis than bare metal stents? Late stent thrombosis: a nuisance in both bare metal and drug-eluting stents. Circulation 115(11): 1433-9; Discussion 1439, 2007

Stent thrombosis in the era of drug-elluting stents FT Die Stentthrombose im Fokus von Drug-eluting Stents. 2007

Potential impact of drug-eluting stents in Sicily: results from a multicenter survey and cost-benefit analysis of drug-eluting stents versus bare metal stents. Italian Heart Journal. Supplement 5(8): 630-638, 2004

Retrospective Study of First-Generation Drug-Eluting Stents, Second-Generation Drug-Eluting Stents and Non-Drug Eluting Stent Methods in the Treatment of Native Vessel In-Stent Restenosis in Real-World Clinical Practice. Heart Lung and Circulation 25(4): 342-351, 2016

Outcome differences with the use of drug-eluting stents for the treatment of in-stent restenosis of bare-metal stents versus drug-eluting stents. American Journal of Cardiology 103(4): 491-495, 2009

The favorable price evolution between bare metal stents and drug eluting stents increases the cost effectiveness of drug eluting stents. International Journal of Cardiology 168(2): 1466-1471, 2013

Treatment of drug-eluting stent restenosis: Comparison between drug-eluting balloon versus second-generation drug-eluting stents from a retrospective observational study. Catheterization and Cardiovascular Interventions 88(4): 522-528, 2016

Coronary arterial remodeling and out-stent plaque change after drug-eluting stent implantation--comparison between zotarolimus-eluting stents and paclitaxel-eluting stents. Circulation Journal 77(2): 363-371, 2013

A Rare Case of Radiation-Induced Meningioma that Occurred Only 3 Years and 6 Months after Radiation Therapy for Oligodendroglioma. No Shinkei Geka. Neurological Surgery 46(6): 515-521, 2018

Application of 3D soft print models of the kidney for treatment of patients with localized cancer of the kidney (a pilot study). Urologiia 2017(6): 12-19, 2017